Roger E. Susi Sells 10,000 Shares of IRadimed Co. (NASDAQ:IRMD) Stock

IRadimed Co. (NASDAQ:IRMD) CEO Roger E. Susi sold 10,000 shares of the company’s stock in a transaction dated Tuesday, January 11th. The shares were sold at an average price of $44.54, for a total value of $445,400.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of IRMD stock opened at $44.04 on Friday. The stock’s 50-day simple moving average is $43.96 and its 200-day simple moving average is $37.73. The firm has a market capitalization of $543.54 million, a PE ratio of 91.75 and a beta of 0.83. IRadimed Co. has a fifty-two week low of $21.65 and a fifty-two week high of $50.88.

IRadimed (NASDAQ:IRMD) last announced its quarterly earnings data on Thursday, October 28th. The medical equipment provider reported $0.23 earnings per share for the quarter, beating analysts’ consensus estimates of $0.17 by $0.06. The business had revenue of $10.91 million for the quarter, compared to analyst estimates of $10.39 million. IRadimed had a return on equity of 9.44% and a net margin of 15.77%. During the same period in the prior year, the company earned $0.09 earnings per share. On average, equities analysts expect that IRadimed Co. will post 0.62 earnings per share for the current year.

Several institutional investors and hedge funds have recently modified their holdings of IRMD. Captrust Financial Advisors purchased a new stake in shares of IRadimed in the third quarter worth about $28,000. BNP Paribas Arbitrage SA boosted its stake in shares of IRadimed by 162.0% in the third quarter. BNP Paribas Arbitrage SA now owns 1,095 shares of the medical equipment provider’s stock worth $37,000 after buying an additional 677 shares during the last quarter. Panagora Asset Management Inc. purchased a new stake in shares of IRadimed in the second quarter worth about $170,000. Goldman Sachs Group Inc. purchased a new stake in shares of IRadimed in the second quarter worth about $210,000. Finally, LPL Financial LLC purchased a new stake in shares of IRadimed in the second quarter worth about $215,000. Hedge funds and other institutional investors own 38.29% of the company’s stock.

IRMD has been the topic of several recent analyst reports. Zacks Investment Research lowered IRadimed from a “buy” rating to a “hold” rating in a research report on Wednesday, January 5th. Roth Capital increased their price objective on IRadimed from $36.00 to $42.00 and gave the company a “buy” rating in a report on Tuesday, November 2nd.

IRadimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging (MRI) compatible medical devices. It also provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

Featured Article: What is a Real Estate Investment Trust (REIT)?

Insider Buying and Selling by Quarter for IRadimed (NASDAQ:IRMD)

Receive News & Ratings for IRadimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRadimed and related companies with MarketBeat.com's FREE daily email newsletter.